Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
OncoC4, Inc.
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Arcus Biosciences, Inc.
Erasca, Inc.
Baylor College of Medicine
GlaxoSmithKline
Mayo Clinic
Erasca, Inc.
Poseida Therapeutics, Inc.
University of Wisconsin, Madison
Jonsson Comprehensive Cancer Center
Baylor College of Medicine
City of Hope Medical Center
Boundless Bio, Inc.
Novartis
Boehringer Ingelheim
AbbVie
AbbVie
Instituto Nacional de Cancer, Brazil
AgonOx, Inc.
Novartis
M.D. Anderson Cancer Center
Pierre Fabre Medicament
National Cancer Institute (NCI)
University of Pennsylvania
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
University of Southern California
National Cancer Institute (NCI)
Nanobiotix
Ohio State University
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
MeiraGTx UK II Ltd
Asher Biotherapeutics, Inc.
Eli Lilly and Company
Exelixis